サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1696297

超個別化医療の世界市場：2025年～2033年

Global Hyper Personalized Medicine Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
超個別化医療の世界市場：2025年～2033年
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の超個別化医療の市場規模は、2024年に2,567億2,000万米ドルに達し、2033年には5,052億6,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは7.9%となる見込みです。

超個別化医療（ハイパー・パーソナライズド・メディスン）とは、患者固有の生物学的、遺伝的、環境的、ライフスタイル的要因に基づいて、個々の患者に合わせた治療や予防戦略を行う先進的なヘルスケアアプローチです。ゲノミクス、プロテオミクス、メタボロミクス、バイオインフォマティクスなどの最先端技術を活用し、患者一人ひとりの分子的・細胞的特徴に高度に特化した治療を提供することで、従来の医療手法を超えるものです。このアプローチは、予知的洞察に基づく予後の改善、副作用の軽減、予防措置の実現により、ヘルスケアに革命をもたらしています。

超個別化医療の需要は急速に拡大しています。例えば、個別化医療連合（PMC）によると、2021年には17の個別化新薬が承認される予定であり、個別化医療は、過去7年間に同機関が承認した新薬の4分の1以上を占めています。この数字は急激な増加を示しています。ほんの10年前までは、毎年承認される新薬に占める個別化薬の割合は10％にも満たないものでした。将来的には、この市場は、高度なテクノロジーと正確で患者中心のケアモデルを統合し、より良い転帰と効率を確保することで、ヘルスケアの提供を変革することになると思われます。

ゲノム技術の進歩の高まりは、超個別化医療市場の成長を大きく後押ししており、予測期間中も市場を牽引すると予想されます。次世代シーケンシング（NGS）のような技術は、ゲノムシーケンシングに必要なコストと時間を劇的に削減しました。J. Craig Venter Instituteによると、ヒトゲノムのシーケンシングコストは2001年の1億米ドル超から現在は1,000ドル未満に低下し、所要時間はわずか数時間であるため、個別化医療はより多くの人々にとってより身近なものとなっています。

主要市場参入企業は、超個別化医療アプローチの開発に注力しており、これが市場の成長をさらに後押ししています。例えば、2024年3月、次世代遺伝子検査・解析企業であるNucleus Genomicsは、個別化医療のメリットをすべての人にもたらすためにDNA解析製品を発売しました。Nucleusは、全ゲノム配列決定の力と革新的なゲノム解析を組み合わせ、一般市民向けに個別化医療の新時代を切り開きました。

CRISPR遺伝子編集技術は、疾患の遺伝的原因を直接標的とすることで、個別化治療の開発を可能にしています。企業はCRISPRを用いて、鎌状赤血球貧血や筋ジストロフィーなどの遺伝性疾患の治療法を模索しており、高度に個別化された、治癒の可能性のある治療法を提供しています。

例えば、2024年5月、コロンビア大学歯学部の研究開発は、特定の細胞や組織へのCRISPR/Cas9ゲノム編集成分の送達を大幅に強化するエクソソームベースのプラットフォーム「safeEXO-Cas」を開発しました。この革新的なプラットフォームは、遺伝子治療と精密医療に革命をもたらす可能性を秘めています。

データ統合の複雑さは、超個別化医療市場の成長を妨げると予想されます。この問題は主に、ゲノム、プロテオーム、臨床、環境データを含む膨大かつ多様なデータセットの統合から生じる。これらの課題は、個別化治療計画を効率的に策定する能力に影響を与え、超個別化医療の採用を遅らせています。

個別化医療には、電子カルテ（EHR）、ゲノムシーケンシング、医療画像、リアルタイムモニタリング機器など、さまざまなソースからの大規模データの統合が必要です。これらのデータは、システム間でサイロ化されていることが多く、標準化されていないため、包括的な洞察を得ることが困難です。例えば、ゲノムデータはあるシステムに保存され、臨床データは別のシステムに保存され、患者の健康記録はさらに別のプラットフォームに保存されるかもしれません。このような統一性の欠如は、個々の患者のためのまとまりのある実用的なプロファイルの作成を複雑にしています。

異なる地域のヘルスケアシステムは、互換性のないテクノロジーを使用していることが多く、電子医療システム間の相互運用性が低いです。例えば、米国医療情報管理協会（AHIMA）の報告によると、米国のヘルスケア組織の80％がデータ統合の問題を経験しており、これは個別化治療の効率に直接影響します。

当レポートでは、世界の超個別化医療市場について調査し、市場の概要とともに、製品タイプ別、技術別、用途別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 超個別化医療市場、製品タイプ別

  • 治療薬
  • 診断薬
  • ソフトウェアソリューション

第6章 超個別化医療市場、技術別

  • ゲノミクス
  • プロテオミクス
  • バイオインフォマティクス
  • 人工知能（AI）
  • その他

第7章 超個別化医療市場、用途別

  • 腫瘍学
  • 心臓病学
  • 神経学
  • 免疫学
  • 希少疾患
  • 感染症
  • その他

第8章 超個別化医療市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • AstraZeneca PLC
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • GE HealthCare
  • Illumina, Inc.
  • Novartis AG
  • Precision Biologics.
  • Abbott Laboratories
  • ASURAGEN, INC.
  • F. Hoffmann-La Roche Ltd
  • Achilles Therapeutics plc
  • QIAGEN NV

第11章 仮定と調査手法

第12章 付録

目次
Product Code: PH8851

The global hyper personalized medicine market reached US$ 256.72 billion in 2024 and is expected to reach US$ 505.26 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033.

Hyper personalized medicine is an advanced healthcare approach that tailors medical treatment and preventive strategies to individual patients based on their unique biological, genetic, environmental and lifestyle factors. It goes beyond traditional medical practices by utilizing cutting-edge technologies like genomics, proteomics, metabolomics and bioinformatics to offer treatments that are highly specific to the molecular and cellular characteristics of each patient. This approach is revolutionizing healthcare by improving outcomes, reducing side effects and enabling preventive measures based on predictive insights.

The demand for hyper personalized medicine is rapidly expanding. For instance, according to the Personalized Medicine Coalition (PMC), With the approval of 17 new personalized medicines in 2021, personalized medicines, account for more than a quarter of the new drugs the agency has approved in, the past seven years. This figure represents a sharp increase. Just a decade ago, personalized medicines accounted for less than 10 percent of the new therapies approved each year. In Future, this market is set to transform healthcare delivery by integrating advanced technologies with precise, patient-centered care models, ensuring better outcomes and efficiency.

Market Dynamics: Drivers & Restraints

Rising Advancements in Genomic Technologies

Rising advancements in genomic technologies are significantly driving the growth of the hyper personalized medicine market and are expected to drive the market over the forecast period. Technologies like Next-Generation Sequencing (NGS) have drastically reduced the cost and time needed for genome sequencing. According to the J. Craig Venter Institute, the cost of sequencing a human genome has dropped from over USD 100 million in 2001 to less than USD 1,000 today and takes only a few hours, making personalized medicine more accessible to a broader population.

Major market players are focussing on the development of hyper personalized medicine approaches, which further fueling the market growth. For instance, in March 2024, Nucleus Genomics, the next-generation genetic testing and analysis company, launched its DNA analysis product to bring the benefits of personalized medicine to everyone. Nucleus combined the power of whole-genome sequencing with innovative genomic analyses, ushering in a new era of personalized medicine for the public.

CRISPR gene-editing technology is enabling the development of personalized therapies by directly targeting the genetic causes of diseases. Companies are using CRISPR to explore treatments for genetic disorders such as sickle cell anemia and muscular dystrophy, offering highly personalized and potentially curative treatments.

For instance, in May 2024, Researchers at Columbia University College of Dental Medicine developed an exosome-based platform, "safeEXO-Cas," that significantly enhances the delivery of CRISPR/Cas9 genome editing components to specific cells and tissues. The potential of this innovative platform is to revolutionize gene therapy and precision medicine.

Complexity of Data Integration

The complexity of data integration is expected to hamper the growth of the hyper personalized medicine market. This issue primarily arises from the integration of vast and varied datasets, which include genomic, proteomic, clinical and environmental data. These challenges impact the ability to efficiently develop personalized treatment plans, slowing the adoption of hyper personalized medicine.

Personalized medicine requires the integration of large-scale data from different sources like electronic health records (EHRs), genomic sequencing, medical imaging and real-time monitoring devices. These data types are often siloed across systems and lack standardization, making it difficult to draw comprehensive insights. For instance, genomic data might be stored in one system, while clinical data is in another, and patient health records are stored in yet another platform. This lack of uniformity complicates the creation of a cohesive, actionable profile for individual patients.

Healthcare systems across different regions often use incompatible technologies, leading to poor interoperability between electronic health systems. For instance, a report by the American Health Information Management Association (AHIMA) indicates that 80% of healthcare organizations in the US experience data integration issues, which directly affects the efficiency of personalized treatments.

Segment Analysis

The global hyper personalized medicine market is segmented based on product type, technology, application and region.

Application:

The oncology from application segment is expected to dominate the hyper personalized medicine market

Cancer is one of the most prevalent diseases worldwide. The increasing prevalence directly increases the demand for effective treatments, particularly in the face of diverse tumor types, this has accelerated the shift toward personalized oncology. This hyper personalized approaches in oncology allow for targeting specific mutations in tumors, offering better outcomes and reducing side effects compared to traditional treatments.

For instance, according to the National Institute of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. According to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.

The use of genomic profiling in oncology allows for identifying genetic mutations that drive cancer progression, enabling more accurate diagnoses and targeted treatments. Technologies like Next-Generation Sequencing (NGS) are extensively used to analyze tumor genomes. For instance, FoundationOne by Foundation Medicine offers comprehensive genomic profiling of solid tumors to identify actionable mutations, guiding the selection of targeted therapies.

Geographical Analysis

North America is expected to hold a significant position in the hyper personalized medicine market

North America, particularly the United States is a global leader in biomedical research, accounting for approximately 60% of the world's total healthcare R&D spending. Significant funding is provided for the development of precision medicine technologies, including genomic profiling, bioinformatics and digital health solutions.

North America benefits from a robust regulatory environment, particularly through organizations like the FDA (Food and Drug Administration) in the United States. The FDA has approved several personalized therapies such as CAR-T cell treatments such as Kymriah for leukemia and checkpoint inhibitors such as Keytruda for various cancers. These approvals drive market growth by providing a clear pathway for the development and commercialization of hyper personalized medicines.

North America leads the adoption of advanced technologies like artificial intelligence (AI), which are pivotal in the development of personalized medicine. For instance, in October 2024, Ataraxis AI emerged from stealth with $4 million. The funding has enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhance the prediction of patient outcomes and enable more precise, personalized treatments. The company also unveiled its first offering, Ataraxis Breast, the world's first AI-native prognostic/predictive test for breast cancer and the most advanced clinically validated test available.

Competitive Landscape

The major global players in the hyper personalized medicine market are AstraZeneca PLC, GE HealthCare, Illumina, Inc., Novartis AG, Precision Biologics., Abbott Laboratories, ASURAGEN, INC., F. Hoffmann-La Roche Ltd., Achilles Therapeutics plc, QIAGEN N.V. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global hyper personalized medicine market report delivers a detailed analysis with 62 key tables, more than 58 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Genomic Technologies
      • 3.1.1.2. Shift Towards Precision Oncology
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Data Integration
    • 3.1.3. Opportunity
      • 3.1.3.1. Technological Advancements into Hyper Personalized Medicine
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Selling Brand
    • 4.1.3. Market Leaders with Established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Hyper Personalized Medicine Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Therapeutics*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Diagnostics
  • 5.4. Software Solutions

6. Hyper Personalized Medicine Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Genomics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Proteomics
  • 6.4. Bioinformatics
  • 6.5. Artificial Intelligence (AI)
  • 6.6. Others

7. Hyper Personalized Medicine Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Oncology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cardiology
  • 7.4. Neurology
  • 7.5. Immunology
  • 7.6. Rare Disorders
  • 7.7. Infectious Diseases
  • 7.8. Others

8. Hyper Personalized Medicine Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Mexico
      • 8.4.6.2. Brazil
      • 8.4.6.3. Argentina
      • 8.4.6.4. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. AstraZeneca PLC*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. GE HealthCare
  • 10.3. Illumina, Inc.
  • 10.4. Novartis AG
  • 10.5. Precision Biologics.
  • 10.6. Abbott Laboratories
  • 10.7. ASURAGEN, INC.
  • 10.8. F. Hoffmann-La Roche Ltd
  • 10.9. Achilles Therapeutics plc
  • 10.10. QIAGEN N.V.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us